Evidence map›Paper›PMID 37333199›Full record

ArticlebioRxiv : the preprint server for biology2023

EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas.

Tanner J DuCote, Xiulong Song, Kassandra J Naughton, Fan Chen, Daniel R Plaugher, Avery R Childress, Abigail R Edgin, Xufeng Qu, Jinze Liu, Jinpeng Liu and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tanner J DuCoteDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
Xiulong SongDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
Kassandra J NaughtonDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
Fan ChenDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
Daniel R PlaugherDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
Avery R ChildressDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
Abigail R EdginDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
Xufeng QuDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA 23219 USA.
Jinze LiuDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA 23219 USA.
Jinpeng LiuDepartment of Cancer Biostatistics, University of Kentucky, Lexington KY 40536 USA.
Fei LiLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York University, New York, NY 10016 USA.
Kwok-Kin WongLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York University, New York, NY 10016 USA.
Christine F BrainsonDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington KY 40536 USA.
University of Kentucky · USNYU Langone Health · USVirginia Commonwealth University · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
University of Kentucky Center for Cancer MetabolismP20GM121327 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jianhang Jia · 2017 to 2026
$25.0M
TRAINING GRANT IN MOLECULAR MECHANISMS OF TOXICITY.T32ES007266 · NIEHS · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI, MELLON, ISABEL W · 1990 to 2020
$3.7M
Interdisciplinary Research Training in Cancer BiologyT32CA165990 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers, KATHLEEN L. O'CONNOR · 2013 to 2026
$3.2M
Targeting Epigenetic Heterogeneity to Improve Lung Cancer Immunotherapy ResponseR01CA237643 · NCI · UNIVERSITY OF KENTUCKY · PI BRAINSON, CHRISTINE FILLMORE · 2019 to 2023
$1.9M
Defining epigenetic vulnerabilities of subtype-specific lung cancersK22CA201036 · NCI · UNIVERSITY OF KENTUCKY · PI BRAINSON, CHRISTINE FILLMORE · 2016 to 2018
$482k
Bronchiolar Dysplasia in COPD is Governed by Loss of Polycomb Repressive Complex 2F31HL151111 · NHLBI · UNIVERSITY OF KENTUCKY · PI BYRD, ARIA · 2020 to 2021
$57k
NCI NIH HHS K22 CA201036NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA237643NCI NIH HHS T32 CA165990NHLBI NIH HHS F31 HL151111NIEHS NIH HHS T32 ES007266NIGMS NIH HHS P20 GM121327
6 · The paper itself

Abstract

Two important factors that contribute to resistance to immune checkpoint inhibitors (ICIs) are an immune-suppressive microenvironment and limited antigen presentation by tumor cells. In this study, we examine if inhibition of the methyltransferase EZH2 can increase ICI response in lung squamous cell carcinomas (LSCCs). Our

Indexed as

epigeneticsEZH2immunotherapyMHCneutrophils

Identifiers

PMID37333199
PMCPMC10274685
OpenAlexW4379931799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.